Anlotinib Plus Docetaxel Versus Docetaxel for Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy : a Multicentre, Double-blind, Randomised Explorative Trial
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Anlotinib (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Sep 2018 Planned End Date changed from 1 Sep 2020 to 1 Oct 2020.
- 13 Sep 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Oct 2019.
- 13 Sep 2018 Planned initiation date changed from 15 Sep 2018 to 15 Oct 2018.